Cancer biomarker discovery: current status and future perspectives

Area of Science:

• Oncology
• Biomarker Discovery
• Genomics and Proteomics

Background:

• Cancer is a complex multigene disease driven by genetic and epigenetic alterations.
• Tumor heterogeneity and cancer stem cells (CSC) present challenges in biomarker development.
• Biomarkers are essential for early cancer detection, staging, and personalized therapy.

Purpose of the Study:

• To review preclinical strategies for cancer biomarker discovery.
• To discuss emerging approaches for identifying sensitive and specific tumor signatures.
• To highlight the role of biomarkers in advancing individualized cancer treatment.

Main Methods:

• Genomic, proteomic, metabolomic, and microRNomic profiling.
• Comparative genome hybridization (CGH) and single nucleotide polymorphism (SNP) analysis.
• Next-generation sequencing (NGS), high-throughput screening (HTS), circulating tumor cells (CTC), CSC markers, and cell-free circulating tumor DNA (ctDNA).

Main Results:

• Powerful genomic and proteomic technologies enable simultaneous analysis of numerous biological molecules.
• These advancements facilitate the discovery of new, sensitive, and specific tumor signatures.
• Biomarker discovery is paving the way for improved cancer detection, monitoring, and treatment selection.

Conclusions:

• Integrated bioinformatic tools enhance the analysis of large-scale molecular data.
• New tumor signatures promise enhanced sensitivity and specificity for cancer diagnostics.
• Individualized cancer treatment strategies are becoming more attainable through advanced biomarker research.